Clinical Trial Update: First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line gemcitabine with or without sunitinib in advanced or metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Sutent (sunitinib)

Snippet

Sponsor: Central European Society for Anticancer Drug Research | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED